Company intelligence / Profile preview

FUSMobile

Alpharetta, Georgia, United Statesfusfoundation.org ↗

Ownership: Private
Development stage: Other

Overview

FUSMobile has developed the Neurolyser XR, a noninvasive high-intensity focused ultrasound system guided by x-ray imaging for ablation of neural tissue to treat chronic pain. The device received CE Mark approval based on a multicenter clinical trial showing 82.6% response rate at 180 days post-procedure with no device-related side effects. Clinical studies are ongoing in Canada, Israel, and the US as part of an FDA IDE pivotal study.

Therapeutic areas: Rheumatology
Modalities: DeviceHigh-intensity focused ultrasound (HIFU)
Industry: Therapeutic Medical Devices

Partnerships

OrbiMed Advisors led first institutional funding roundacademic collaborations with McGill University and Silver Medical Group for pilot studies

Beyond the preview

Go deeper on FUSMobile.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FUSMobile.

Explore the full profile